特发性肺纤维化患者血清透明质酸、层粘连蛋白的变化及意义

Abstract
Figure/Table
References (20)
Related Citation (5)

Download: PDF (492 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the level and significance of serum hyaluronic acid (HA) and laminin (LN) in patients with idiopathic pulmonary fibrosis (IPF). Methods From June 2014 to June 2016 , in Department of Respiratory Diseases, Affiliated Hospital of Hangzhou Normal University, 38 patients with IPF were selected as control group, and 30 healthy persons without smoking at same time were selected as control group. The levels of serum HA and LN in IPF patients and cotrol group were detected by radioimmunoassay. And the correlation between serum HA, LN with lung function, 6-minute walk test (6MWT) and dyspnea score was evaluated. Results Compared with the control group, the levels of serum HA and LN of patients in IPF group were significantly higher (P < 0.05). The levels of serum HA and LN in patients with IPF were negatively correlated with FVC, FEV1 and DLCO (all r < 0, P < 0.05 or P < 0.01); HA and LN were negatively correlated with 6MWT (r = -0.637, -0.705, P < 0.01); the levels of serum HA and LN in IPF patients were positively correlated with mMRC score (r = 0.618, 0.552, P < 0.05). Conclusion These data suggest that serum HA and LN may be useful biomarkers to estimate the severity and treatment effect of patients with IPF.

Key words： Idiopathic pulmonary fibrosis Hyaluronic acid Laminin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xueyuan LI Yaqian FENG Zhemin HE Wenbo SUN Yibo

Cite this article:

CHEN Xueyuan LI Yaqian FENG Zhemin HE Wenbo SUN Yibo. Level and significance of serum hyaluronic acid and laminin in patients with idiopathic pulmonary fibrosis[J]. 中国医药导报, 2017, 14(16): 44-46.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I16/44

[1] Travis WD，Costabel U，Hansell DM，et al. An official American Thoracic Society/European Respiratory Society statement：Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med，2013，188（6）：733-748.
[2] King TE Jr，Pardo A，Selman M. Idiopathic pulmonary fibrosis [J]. Lancet，2011，378（9807）：1949-1961.
[3] Sgalla G，Biffi A，Richeldi L. Idiopathic pulmonary fibrosis：Diagnosis，epidemiology and natural history [J]. Respirology，2016，21（3）：427-437.
[4] Raghu G，Collard HR，Egan JJ，et al. An official ATS/ERS/JRS/ALAT statement：idiopathic pulmonary fibrosis：evidence-based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med，2011，183（6）：788-824.
[5] Raghu G，Rochwerg B，Zhang Y，et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline：Treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline [J]. Am J Respir Crit Care Med，2015， 192（2）：e3-e19.
[6] King TE Jr，Tooze JA，Schwarz MI，et al. Predicting survival in idiopathic pulmonary fibrosis：scoring system and survival model [J]. Am J Respir Crit Care Med，2001，164（7）：1171-1181.
[7] Ohshimo S，Yokoyama A，Hattori N，et al. KL-6，a human MUC1 mucin，promotes proliferation and survival of lung fibroblasts [J]. Biochem Biophys Res Commun，2005，338（4）：1845-1852.
[8] Ohshimo S，Ishikawa N，Horimasu Y，et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis [J]. Respir Med，2014，108（7）：1031-1039.
[9] Greene KE，King TE Jr，Kuroki Y，et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis [J]. Eur Respir J，2002，19（3）：439-446.
[10] Kinder BW，Brown KK，McCormack FX，et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis [J]. Chest ，2009，135（6）：1557-1563.
[11] Prasse A，Probst C，Bargagli E，et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med，2009， 179（8）：717-723.
[12] Cai M，Bonella F，He X，et al. CCL18 in serum，BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases [J]. Respir Med，2013，107（9）：1444-1452.
[13] DePianto DJ，Chandriani S，Abbas AR，et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis [J]. Thorax，2015，70（1）：48-56.
[14] Prasse A，Müller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis [J]. Respirology，2009，14（6）：788-795.
[15] Zhang Y，Kaminski N. Biomarkers in idiopathic pulmonary fibrosis [J]. Curr Opin Pulm Med，2012，18（5）：441-446.
[16] Song JW，Do KH，Jang SJ，et al. Blood biomarkers MMP-7 and SP-A：predictors of outcome in idiopathic pulmonary fibrosis [J]. Chest，2013，143（5）：1422-1429.
[17] Guiot J，Henket M，Corhay JL，et al. Sputum biomarkers in IPF：Evidence for raised gene expression and protein level of IGFBP-2，IL-8 and MMP-7 [J]. PLoS One，2017， 12（2）：e0171344.
[18] White ES，Xia M，Murray S，et al. Plasma surfactant protein-d，matrix metalloproteinase-7，and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias [J]. Am J Respir Crit Care Med，2016，194（10）：1242-1251.
[19] Inokoshi Y，Tanino Y，Wang X，et al. Clnical Significance of Serum Hyaluronan in Chronic Fibrotic Interstitial Pneumonia [J]. Respirology，2013，18 （8）：1236-1243.
[20] Lappi-Blanco E，Kaarteenaho-Wiik R，Salo S，et al. Laminin-5 gamma 2 chain in cryptogenic organizing pneumonia and idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med，2004，169（1）：27-33.